|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis of beta-catenin in 11 HBs demonstrated nuclear/cytoplasmic accumulation of the protein in all tumors analysed, with predominant nuclear beta-catenin immunostaining in undifferentiated cells.
|
10698519 |
2000 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that activation of Yes-associated protein (YAP) is a major molecular event in HB development, as activated YAP synergizes with mutant β-catenin to promote HB formation in mice (YAP/β-catenin).
|
29088718 |
2017 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although mutations in CTNNB1 were not found in the second hepatoblastoma, nuclear accumulation of beta-catenin was detected.
|
14692643 |
2004 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Comparison to previously published data on this series of HB revealed that the number of chromosomal imbalances was significantly higher in HB tumors with loss of heterozygosity on 11p (P = 0.03), whereas in five of 10 HB biopsies without chromosomal imbalances, beta-catenin gene mutations were found.
|
10934159 |
2000 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
To address beta-catenin's capability in maintaining the malignant phenotype in established pediatric HB and HCC cell lines, HuH-6 and HepG2, harboring mutated and overexpressed beta-catenin, we carried out a series of in vitro analyses through a transfection of short interfering RNAs (siRNAs) to generate a loss-of-function model.
|
16465377 |
2006 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
When TEAD2 DNA-binding domain was fused with virus protein 16 transcriptional activation domain, it synergized with activated β-catenin to promote HB formation in vivo.
|
30794805 |
2019 |
|
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
A histological examination revealed all HBL cases involving tumors without detectable CTNNB1 gene alterations to show high expression of beta-catenin, thus indicating the accumulation of beta-catenin to be a common event in malignant PLTs, including HBL and hepatocellular carcinoma.
|
16465411 |
2006 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
It is therefore concluded that immunohistochemical analysis of beta-catenin might be a useful clinical tool for estimating the prognosis for patients with hepatoblastoma.
|
11276007 |
2001 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
beta-catenin mutation and RASSF1A methylation were found in 22 (56.4%) and 15 (38.5%) of 39 hepatoblastomas, respectively, but SFRPs methylation was not found in any of them.
|
16937357 |
2007 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Deregulation of the APC/beta-catenin pathway occurs in a consistent fraction of hepatoblastomas, with mutations in the APC and beta-catenin genes implicated in familial adenomatous polyposis-associated and sporadic hepatoblastomas, respectively.
|
17962810 |
2008 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Transcriptomic analysis showed a strong correlation in gene expression between HB in the Yap1-β-catenin model and HB patient cohorts.
|
30863496 |
2019 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Tumors derived from 56 HBL cases treated with the Japanese Study Group for Pediatric Liver Tumors (JPLT) Protocol-2 were analyzed for oncogenic mutations (missense mutations and interstitial deletions in the third exon) of the CTNNB1 gene-encoding β-catenin and for the expression levels of telomerase reverse transcriptase (TERT).
|
22152854 |
2011 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Correction: mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development.
|
31645895 |
2019 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
All 3 (100%) mixed epithelial and mesenchymal HBL harbored CTNNB1 mutation.
|
29079173 |
2017 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings suggested the activation of the Wnt pathway in HB, which was confirmed by immunohistochemical staining of the β-catenin in 42 HB tumors.
|
24912477 |
2014 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recently, disregulation of the Wnt/beta-catenin pathway, attributable to abnormalities of the beta-catenin gene, has been reported to be a major event in the development of hepatocellular carcinomas and hepatoblastomas.
|
12203220 |
2002 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In CTNNB1-mutated hepatoblastoma, expression of GS was only detected in tumour areas with epithelial, not with mesenchymal differentiation.
|
21237236 |
2011 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma.
|
10754205 |
2000 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Overexpression of Tbx3 is closely associated with the mutational status of beta-catenin in murine liver tumors induced by Myc as well as in human hepatocellular carcinomas and hepatoblastomas.
|
17283120 |
2007 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus, we demonstrate that β-catenin point mutants can also collaborate with YAP1 in HB development, albeit with a distinct molecular profile from the deletion mutant, which may have implications in both biology and therapy.
|
30794807 |
2019 |
|
Hepatoblastoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Hepatoblastoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We detected nuclear β-catenin immunostaining in nearly all untreated HBs, including in fetal and embryonal epithelial components and in mesenchymal elements.
|
28277286 |
2017 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
By contrast, the expression levels of epithelial-cadherin (E-cadherin) and cytosolic accumulation of β-catenin, the two most prominent markers involved in epithelial-mesenchymal transition (EMT), were reduced in liver specimens from patients with metastatic HB compared with that of healthy adjacent control tissue.
|
25695679 |
2015 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Whole-exome sequencing identified HB as a genetically very simple tumour (2.9 mutations per tumour) with recurrent mutations in ß-catenin (CTNNB1) (12/15 cases) and the transcription factor NFE2L2 (2/15 cases).
|
25135868 |
2014 |